Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose naltrexone for persistent symptoms in Hashimoto's hypothyroidism
ACTRN12625000131459Phase 2Recruiting
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Hashimoto's disease and hypothyroidism comparing Naltrexone plus thyroxine with Placebo plus thyroxine (2 arms). Primary endpoint: Change in thyroid-specific quality of life. Started Sep 2025; status: recruiting.
02
Drugs
naltrexone
03
Conditions
Hashimoto's diseasehypothyroidism
Beyond the preview
Go deeper on ACTRN12625000131459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000131459.